Uniformed Services University to Release Topline Data
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Immuron Limited reports that the Uniformed Services University has released topline results from a clinical trial evaluating a third-party manufactured product for maintaining gut health during deployment and travel. The primary endpoint did not reach statistical significance, and Immuron identified several factors that may have influenced this outcome, including dosing timing and compliance with study procedures. The company plans to propose a clinically validated dosing schedule at an upcoming meeting with the FDA based on these findings. Immuron continues to collaborate with military research institutions on developing vaccines targeting specific pathogens.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Immuron
- Immuron New U.S. Department of Defense Award & Clinical Trial Update
- Immuron IMM-529 IND approved by FDA
- Immuron Announces Clinical Trial Update
- Clinical Trial Update
- Immuron launch PROIBS for IBS
Later from Immuron
- Immuron Reports Continued Sales Growth
- Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live stream
- Appendix 4D and Half Year Report
- Immuron Reports HY26 Results and Strategic Reset
- Strategic Update and HY26 Results
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron